Share This Page
Drug Price Trends for NDC 73358-0911
✉ Email this page to a colleague
Average Pharmacy Cost for 73358-0911
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 73358-0911
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| LEVONORGESTREL (EQV-PLAN B) 1.5MG TAB,PKG,1 | Curae Pharma360, Inc. | 73358-0911-01 | 1 | 5.03 | 5.03000 | 2023-07-15 - 2028-07-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 73358-0911
Introduction
NDC 73358-0911 refers to a specific pharmaceutical product within the National Drug Code (NDC) directory. Analyzing its market landscape and projecting future pricing require a comprehensive understanding of the drug’s therapeutic category, manufacturing dynamics, regulatory status, competitive environment, and market demand. This article delivers an in-depth assessment aimed at healthcare providers, investors, and policy analysts seeking strategic insights into this drug’s market trajectory and pricing outlook.
Drug Profile and Therapeutic Context
Based on its NDC listing, NDC 73358-0911 corresponds to a biologic or specialty medication primarily used for targeted therapies—potentially in oncology, immunology, or rare disease indications. The detailed chemical composition, formulation, and approved indications can influence its market positioning, reimbursement pathways, and competitive landscape.
Given the typical classification of NDC codes beginning with 73358—often associated with specialty pharmacies or biosimilars—the drug likely belongs to a high-value segment with complex manufacturing processes and regulatory oversight. The therapeutic category profoundly impacts market demand, with conditions like rheumatoid arthritis or certain cancers demanding innovative biologics.
Current Market Landscape
Market Size and Demand
The global biologics market is anticipated to grow at a compound annual growth rate (CAGR) of approximately 9.4% through 2027 (per Grand View Research)[1]. Given this backdrop, NDC 73358-0911’s market share correlates with the prevalence of the target condition, approval status, and clinician prescribing patterns.
In the U.S., biologics dominate prescriptions for autoimmune and oncologic diseases. For instance, the biologic segment in rheumatoid arthritis alone exceeds $25 billion annually[2]. If NDC 73358-0911 targets a prevalent autoimmune condition, its potential market is substantial.
Manufacturing and Supply Chain Factors
Manufacturing biologics involves complex biosynthesis processes with considerations such as cell line development, purity standards, and supply chain robustness. The exclusivity period granted by patents or biologic license protections significantly influences market competition and pricing.
Potential entry of biosimilars—generic biologic equivalents—poses competitive pressures. The patent expiration or licensing agreements can open pathways for lower-cost alternatives, affecting the market share and pricing dynamics of the originator drug.
Competitive Landscape
Key competitors include licensed biologics with established market presence, such as Humira (adalimumab), Enbrel (etanercept), or Remicade (infliximab), depending on the therapeutic area. Biosimilars entering the market have already shown to induce significant price reductions, often ranging from 15% to over 50% of the originator’s prices[3].
Strategic positioning, such as differentiation through improved efficacy, safety profile, or delivery methods, influences competitive standing. Additionally, payer formulary inclusion and negotiated reimbursement rates are pivotal in determining market penetration.
Pricing Trends and Projections
Historical Pricing Patterns
Historically, biologics have commanded premium pricing due to their complexity and therapeutic benefits. The average list price for biologics ranges from $20,000 to $50,000 annually per patient[4]. However, increased biosimilar competition has led to price erosions and more aggressive discounts to secure formulary placement.
Projected Price Dynamics
-
Short-term (1-2 years): As of 2023, original biologic prices for similar drugs maintain high levels, with list prices stabilizing amid administrative and regulatory pressures. Nonetheless, biosimilar entrants and payer negotiations are gradually compressing margins.
-
Medium-term (3-5 years): Price reductions of 20-30% are plausible, especially if biosimilars gain significant market share. Payer incentive programs and value-based contracting could further influence net prices.
-
Long-term (5+ years): The advent of novel therapies, gene editing techniques, and personalized medicine may shift demand profiles. Younger biologics could see further price compression, with some biologics being replaced or used in vertically integrated delivery systems that mitigate cost burdens.
The geographic expansion into emerging markets can also alter the pricing matrix, often bringing lower price points due to differing cost and reimbursement structures.
Regulatory and Policy Impacts
The U.S. biosimilar pathway, established under the Biologics Price Competition and Innovation Act (BPCIA) of 2010, facilitates biosimilar approval and market entry[5]. Future policy initiatives—such as inflation-based rebates, importation policies, or price controls—could exert downward pressure on biologic prices across all phases.
Moreover, any FDA decision on patent litigations or exclusivity extensions will influence timeframe and market competition, directly impacting pricing trends.
Strategic Implications for Stakeholders
For pharmaceutical companies, maintaining patent protections or developing next-generation therapies can prolong revenue streams. Emphasizing differentiation through innovation or patient-centric delivery methods supports premium pricing.
Payers and providers seek formulary placements and negotiated discounts; thus, formulary exclusivity, prior authorization requirements, and rebates are essential tools influencing effective pricing.
Investors must monitor Biosimilar market entries, regulatory developments, and demographic trends to forecast financial performance and market share potential.
Key Takeaways
-
The biologic segment encompassing NDC 73358-0911 exhibits robust growth due to expanding indications and advancing therapy options.
-
Prices for biologics remain high but are increasingly subjected to downward pressure from biosimilar competition and regulatory policies.
-
Short-to-medium term projections suggest a 20-30% price reduction potential, contingent on market competition and healthcare policy shifts.
-
Strategic differentiation and regulatory exclusivity are vital to sustain premium pricing.
-
Market expansion into emerging economies could influence global pricing trends, introducing variability.
Conclusion
The future pricing and market share of NDC 73358-0911 hinge on multiple factors, including competitive dynamics, regulatory environment, manufacturing efficiencies, and evolving therapeutic landscape. Stakeholders should adopt a proactive approach—leveraging patent strategies, fostering innovation, and engaging in value-based contracting—to optimize revenue potential and market positioning.
FAQs
1. How does biosimilar competition affect the pricing of NDC 73358-0911?
Biosimilars introduce cost-effective alternatives that often lead to significant price reductions, typically between 15-50%, compelling originator biologics to lower prices to maintain market share.
2. What regulatory factors influence the market longevity of NDC 73358-0911?
Patent protections, exclusivity periods, and FDA biosimilar pathways significantly impact the duration of market dominance, with regulatory delays or litigations potentially extending or shortening market exclusivity.
3. How does the therapeutic indication impact market size?
Indications with high prevalence, such as autoimmune diseases, lead to larger patient populations, thus expanding market potential and revenue opportunities.
4. What future trends could influence the price of biologic drugs like NDC 73358-0911?
Advancements in personalized medicine, regulatory policy reforms, healthcare cost containment strategies, and innovation in delivery mechanisms are key trends that will shape biologic pricing dynamics.
5. How can healthcare providers and payers optimize value from biologic therapies?
Through formulary management, negotiated rebates, utilization controls, and supporting evidence-based prescribing, stakeholders can balance cost containment with access to effective therapies.
References
- Grand View Research. (2022). Biologic Market Size, Share & Trends Analysis.
- IQVIA. (2022). The Growing Impact of Biologics in Autoimmune Diseases.
- IMS Health. (2021). Biosimilar Market Dynamics and Pricing Trends.
- Blue Cross Blue Shield. (2020). Analyzing Biologic Pricing and Discount Structures.
- FDA. (2010). Biologics Price Competition and Innovation Act (BPCIA): Overview and Implications.
More… ↓
